1 completed, 1 not yet recruiting, 1 terminated, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Clear-cell Renal Cell Carcinoma: new trials by email Literature Review of Clear-cell Renal Cell Carcinoma trials Research Report on Clear-cell Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer Proteomic profiling of urinary EVs, Blood sample collection - Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma | Not yet recruiting | Mayo Clinic | 300 | 2026-07-15 | 2026-02-27 | |
| Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies Sitravatinib, Nivolumab, Ipilimumab - Clear-Cell Renal Cell Carcinoma | Phase 1 | Completed | Mirati Therapeutics Inc. | 22 | 2020-08-11 | 2024-06-05 |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma Avelumab, Sunitinib - Clear-cell Renal Cell Carcinoma, RCC | Phase 2 | Withdrawn | Guru Sonpavde | 2017-05-23 | 2022-02-15 | |
| A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma CDX-014 - Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma | Phase 1 | Terminated | Celldex Therapeutics | 16 | 2016-06-01 | 2020-06-04 |
Carcinoma, Renal Cell (4) · Kidney Neoplasms (3) · Kidney Diseases (1) · Ovarian Neoplasms (1)
Adenocarcinoma (4) · Carcinoma (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Urologic Diseases (4) · Urologic Neoplasms (4) · Kidney Diseases (3) · Adnexal Diseases (1)
Ipilimumab (1) · Nivolumab (1) · Sunitinib (1) · avelumab (1) · sitravatinib (1)
Celldex Therapeutics (1) · Guru Sonpavde (1) · Mayo Clinic (1) · Mirati Therapeutics Inc. (1)
United States (4)
Curtis Chin, MD (1) · Fabrice Lucien-Matteoni, MD (1) · Guru Sonpavde, M.D. (1)